02.17.2021 Wall Street Looks Again at Bluebird, Rivals, After Gene-Therapy Setback J.P. Morgan’s Cory Kasimov moved bluebird bio to Neutral from Overweight in response to news it is suspending trials of a treatment for sickle cell disease.
